Kay Davies group’s research programme has two major strands. The first is focussed on the development of an effective treatment for the muscle wasting disease, Duchenne muscular dystrophy (DMD). The second strand is focussed on using the mouse as a model to determine the molecular basis of psychiatric, neurodegenerative and neurodevelopmental diseases.
Kay Davies group’s research programme is focussed on the development of an effective treatment for the muscle wasting disease, Duchenne muscular dystrophy (DMD). DMD is a progressive muscle wasting disease caused by the absence of the large protein, dystrophin in all muscle cells of patients. At present there is no effective treatment for the disorder although there are various promising approaches. Some strategies can only be used for certain mutations and the challenge of many therapeutic approaches is the targeting of all muscles including the heart. The Davies group has focused their efforts on the development of an effective therapy which would be applicable to all patients and potentially target all muscles. They are working out a way to increase levels of ad dystrophin-related protein, utrophin, which will compensate for the missing dystrophin. They are also working with other groups using different approaches to develop combination therapies which should show greater clinical benefit.
Further details of Kay Davies’s research can be found on her webpage at the Department of Physiology, Anatomy and Genetics.